Skip to main content
Thiogenesis Therapeutics, Corp. logo

Thiogenesis Therapeutics, Corp. — Investor Relations & Filings

Ticker · TTI ISIN · CA88410L1022 LEI · 9845006CBA639FFD6454 TSXV Manufacturing
Open in API
Filings indexed 130 across all filing types
Latest filing 2026-04-16 Investor Presentation
Country CA Canada
Listing TSXV TTI

About Thiogenesis Therapeutics, Corp.

https://www.thiogenesis.com/

Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company specializing in the development of New Chemical Entities (NCEs), specifically novel thiol-based prodrugs. These next-generation sulfur-containing therapeutics are designed to restore redox balance and mitigate inflammation, key drivers in inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102, is a novel cysteamine prodrug engineered to overcome the limitations of legacy thiol therapies, offering enhanced tolerability, bioavailability, and improved dosing profiles. TTI-0102 is currently being evaluated for unmet pediatric medical needs, including nephropathic cystinosis (with a pivotal Phase 3 trial planned following an expected 2026 IND filing), MELAS (in Phase 2), and other conditions such as Leigh syndrome spectrum.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Investor Presentation Classification · 94% confidence The document is a corporate press release announcing that the company’s management will present at an upcoming healthcare investor conference, including date, time, presenters, and overview of the presentation. It is not actual financial results, an AGM or proxy, nor a regulatory notice of share transactions or legal matter. This is an announcement of an investor presentation event. Therefore, it falls under Investor Presentation (IP).
2026-04-16 English
News release - English.pdf
Regulatory Filings Classification · 80% confidence The document is a company press release announcing that management will present at an upcoming healthcare investor conference. It does not provide actual presentation slides (Investor Presentation), detailed financial results (Earnings Release or Interim Report), nor is it a formal annual/quarterly report. It is an announcement to the market/disclosure of an investor event. Since there is no specific category for press releases, it falls under the general “Regulatory Filings” fallback category (RNS).
2026-04-16 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Thiogenesis Therapeutics regarding a new investigator-initiated study and a program update for their drug candidate TTI-0102. It provides business and clinical development updates rather than financial results, governance changes, or regulatory filings. As it is a general corporate announcement regarding company operations and clinical progress, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for corporate news releases that do not fit into more specific categories like earnings or M&A.
2026-02-02 English
News release - English.pdf
Earnings Release Classification · 98% confidence The document is a press release issued by Thiogenesis Therapeutics regarding the presentation of clinical trial data at a medical conference (Mitocon 2026). It details study highlights, clinical outcomes, and pharmacokinetic/pharmacodynamic findings. As it is a corporate announcement of clinical trial results rather than a formal regulatory filing, a financial report, or a transcript, it falls under the category of general regulatory announcements/press releases. Q1 2026
2026-01-23 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Thiogenesis Therapeutics announcing that an abstract for their Phase 2 clinical trial has been accepted for a presentation at a medical conference (Mitocon 2026). It provides company background, clinical trial context, and forward-looking statements. Since it does not fit into specific categories like financial reports, board changes, or dividend notices, and is a general corporate announcement distributed via a news wire service (Newsfile Corp), it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for general corporate news.
2026-01-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Thiogenesis Therapeutics regarding the company's plans to initiate a Phase 3 clinical trial for its drug candidate TTI-0102. It provides details on the drug's mechanism, the clinical trial design, and the company's background. It does not constitute a formal financial report (10-K, IR), a transcript, or a governance document. As it is a general corporate announcement regarding business operations and clinical development, it falls under the 'Regulatory Filings' (RNS) category as a standard corporate press release.
2025-11-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.